Stefan de Vogel

Astellas Pharma Europe B.V., Leiden, the Netherlands

Presentation(s):

• OP-25B - Cardiovascular Risk in Users of Mirabegron Relative to Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-interventional, Real-world Data Safety Study

  Tuesday, August 24, 2021
  1:45 PM – 3:30 PM US Eastern Time